EP1379545A2 - Method for producing stable, regeneratable antibody arrays - Google Patents
Method for producing stable, regeneratable antibody arraysInfo
- Publication number
- EP1379545A2 EP1379545A2 EP02745239A EP02745239A EP1379545A2 EP 1379545 A2 EP1379545 A2 EP 1379545A2 EP 02745239 A EP02745239 A EP 02745239A EP 02745239 A EP02745239 A EP 02745239A EP 1379545 A2 EP1379545 A2 EP 1379545A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibody
- protein
- arrays
- antibodies
- producing stable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000003491 array Methods 0.000 title claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 7
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 8
- 108091008324 binding proteins Proteins 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 101710120037 Toxin CcdB Proteins 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 2
- 230000003100 immobilizing effect Effects 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims description 2
- 150000004706 metal oxides Chemical class 0.000 claims description 2
- 230000007261 regionalization Effects 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 5
- 238000011161 development Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003498 protein array Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
Definitions
- the invention relates to a method for producing stable, regenerable antibody arrays using immobilized antibody binding proteins which can specifically recognize the Fc part of antibodies.
- Arrays with biological test molecules are also called biochips, particularly in miniaturized form. Proven examples of such arrays are:
- Nucleic acid arrays from DNA fragments, cDNAs, RNAs, PCR products, plasmids, bacteriophages, synthetic oligonucleotides or synthetic PNA oligomers which are read out by means of hybridization (formation of a double-stranded molecule) on complementary nucleic acid analytes and connecting arrays made of synthetic ones Peptides, their analogs, such as peptoids, oligo-carbamates etc. or generally organic chemical compounds, which are read out by binding to affine protein or other analytes or by enzymatic conversion.
- Such arrays are currently manufactured according to two different principles by placing the test molecules on already prepared material surfaces: a) by spreading the solution of pre-prepared test compounds once on the surface
- Previously known chip configurations use either a right-angled x / y arrangement, which is produced with appropriately manufactured photolithography or printing masks, or a circular r ⁇ arrangement, which is generated by a rotational movement of the chip surface (r ⁇ -arrays) and a rapidly clocked metering device becomes. This enables densities of up to 1 million test connections per cm 2 or a few square micrometers per individual surface to be achieved.
- the invention thus relates to a method for producing stable, regenerable antibody arrays, in which
- the invention further relates to an antibody array which can be obtained by the method according to the invention, a medical or diagnostic device which has an antibody array according to the invention, and a kit which has an antibody array according to the invention and detection reagents for qualitative or quantitative determination contains bound antigens which have been bound to an antibody array according to the invention.
- the invention further specifies the use of an antibody array according to the invention or a medical or diagnostic device according to the invention for the qualitative or quantitative determination of antigens.
- Advantageous and / or preferred embodiments of the invention are the subject of the dependent claims.
- the planar carrier has a surface made of glass, metal, metal oxides, semimetal oxides or plastic.
- the antibody binding protein is selected from Fc-specific secondary antibodies, protein A and protein G.
- the antigen to be determined is a protein.
- the specific antibodies are "directed” immobilized, i.e. via their Fc part in order not to influence the antigen recognition through the coupling.
- a grid of proteins that specifically recognize the Fc part of the specific antibodies is covalently bound to the chip surface in question (eg derivatized Fc-specific secondary antibodies or protein A or protein G molecules).
- Protein / antibody or antibody / antibody complexes are achieved by chemical covalent crosslinking, where be used for common reagents according to the requirements.
- chemical covalent crosslinking In addition to the stabilization of the protein-protein interactions, there is also an intramolecular stabilization of the specific antibodies, ie a chemical cross-linking of their subunits.
- Antibody arrays with the highest stability result, which on the one hand prevent dissociation of the special antibodies, eg during storage, and on the other hand also make it possible to treat the antibody arrays under stringent conditions, such as high salt concentrations or low or high pH to prevent non-specific or low affinity interactions with the antibody matrix. This also enables a correspondingly stringent pretreatment of the protein mixtures to be analyzed.
- the whole process delivers stable and regenerable antibody arrays.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Verfahren zur Herstellung stabiler, regenerierbarer Process for producing stable, regenerable
Antikörper-ArraysAntibody arrays
Die Erfindung betrifft ein Verfahren zur Herstellung stabi- 1er, regenerierbarer Antikörper-Arrays unter Verwendung von immobilisierten Antikörperbindungsproteinen, die spezifisch den Fc-Teil von Antikörpern erkennen können.The invention relates to a method for producing stable, regenerable antibody arrays using immobilized antibody binding proteins which can specifically recognize the Fc part of antibodies.
Sammlungen von großen Zahlen unterschiedlicher Testverbindun- gen, die auf einer ebenen Fläche geordnet abgelegt/immobilisiert werden, werden im wissenschaftlichen Sprachgebrauch als Arrays bezeichnet; vgl. z. B. EP 0 373 203 und EP 0 619 321. Solche Arrays erlauben das schnelle simultane Testen aller Verbindungen durch Interaktionsanalyse, und zwar mit ei- nem Analyten oder einem Gemisch von Analyten in biologischen Proben. Der Vorteil eines Arrays gegenüber dem simultanen Testen von immobilisierten Testverbindungen auf beweglichen Elementen, wie z. B. auf Perlen (Beads) , besteht darin, dass in einem Array die Art (chemische Struktur und/oder Identi- tat) der immobilisierten Testmoleküle genau durch den Ort in der Arrayfläche bekannt ist und ein örtliches Testsignal somit sofort einer Molekülart zugeordnet werden kann. Insbesondere in miniaturisierter Form werden Arrays mit biologischen Testmolekülen auch Biochips genannt. Bewährte Beispiele für solche Arrays sind:Collections of large numbers of different test compounds, which are stored / immobilized in an orderly manner on a flat surface, are called arrays in scientific parlance; see. z. B. EP 0 373 203 and EP 0 619 321. Such arrays allow the rapid simultaneous testing of all compounds by means of interaction analysis, specifically with an analyte or a mixture of analytes in biological samples. The advantage of an array over the simultaneous testing of immobilized test connections on moving elements, such as B. on beads, consists in the fact that the type (chemical structure and / or identity) of the immobilized test molecules in an array is exactly known by the location in the array area and a local test signal can thus be immediately assigned to a type of molecule , Arrays with biological test molecules are also called biochips, particularly in miniaturized form. Proven examples of such arrays are:
Nucleinsäure-Arrays aus DNA-Fragmenten, cDNAs, RNAs, PCR- Produkten, Plasmiden, Bacteriophagen, synthetischen Oligo- nucleotiden oder auch synthetischen PNA-Oligomeren, welche mittels Hybridisierung (Bildung eines Doppelstrangmoleküls) an komplementäre Nucleinsäureanalyten ausgelesen werden und Verbindungs-Arrays aus synthetischen Peptiden, deren Analoga, wie Peptoide, Oligo-Carbamate usw. oder allgemein organisch chemischen Verbindungen, welche mittels Bindung zu affinen Protein- oder anderen Analyten oder mittels enzymatischer Umsetzung ausgelesen werden.Nucleic acid arrays from DNA fragments, cDNAs, RNAs, PCR products, plasmids, bacteriophages, synthetic oligonucleotides or synthetic PNA oligomers, which are read out by means of hybridization (formation of a double-stranded molecule) on complementary nucleic acid analytes and connecting arrays made of synthetic ones Peptides, their analogs, such as peptoids, oligo-carbamates etc. or generally organic chemical compounds, which are read out by binding to affine protein or other analytes or by enzymatic conversion.
Dahingegen befinden sich Protein-Arrays aus Antikörpern, in Zellen exprimierten Proteinen und Phagen-Fusionsproteinen (Phage Display) noch im Entwicklungsstadium (s.u.). Anwendungen finden solche Arrays, die hierfür entwickelten Methoden und Geräte in der biologischen Grundlagenforschung, aber ins- besondere auch in der medizinischen Diagnostik und pharmazeutischen Wirkstoffentwicklung. Auch andere naturwissenschaftliche Forschungsrichtungen, wie z. B. die Katalysatorentwicklung und Materialwissenschaften, beginnen, solche Konzepte erfolgreich zu übernehmen. Voraussetzung für den vorteilhaf- ten routinemäßigen Einsatz solcher Arrays ist deren kostengünstige, schnelle und vollautomatische Herstellung mit einer hohen Dichte und Diversität an Teststrukturen (Informationsgehalt) .In contrast, protein arrays made of antibodies, proteins expressed in cells and phage fusion proteins (phage display) are still in the development stage (see below). Such arrays, the methods and devices developed for them are used in basic biological research, but in particular also in medical diagnostics and pharmaceutical active ingredient development. Other scientific research directions, such as B. catalyst development and materials science begin to successfully adopt such concepts. A prerequisite for the advantageous routine use of such arrays is their cost-effective, fast and fully automated production with a high density and diversity of test structures (information content).
Solche Arrays werden zur Zeit nach zwei verschiedenen Prinzipien durch Ablegen der Testmoleküle auf bereits vorbereiteten Materialoberflächen hergestellt: a) durch einmaliges Verteilen der Lösung vorgefertigter Testverbindungen auf der OberflächeSuch arrays are currently manufactured according to two different principles by placing the test molecules on already prepared material surfaces: a) by spreading the solution of pre-prepared test compounds once on the surface
b) durch wiederholte serielle Verteilung der Lösungen von Bausteinen für die chemische Synthese der Testverbindungen in si tu auf der Oberfläche.b) by repeated serial distribution of the solutions of building blocks for the chemical synthesis of the test compounds in si tu on the surface.
Eine aktuelle Übersicht gibt S. Wöffl in: transcript Laborwelt 2000, 3, 13-20) .S. Wöffl gives a current overview in: transcript Laborwelt 2000, 3, 13-20).
Bisher bekannte Chip-Konfigurationen nutzen entweder eine rechtwinklige x/y Anordnung, die mit entsprechend gefertigten Photolithographie- bzw. Druckmasken erzeugt wird, oder eine kreisförmige rφ-Anordnung, welche durch eine Rotationsbewegung der Chipoberfläche (rφ-Arrays) und einer schnell getakteten Dosiervorrichtung erzeugt wird. Damit können Dichten von bis zu 1 Millionen Test-Verbindungen je cm2 oder von we- nigen Quadratmicrometern je Einzelfläche erreicht werden.Previously known chip configurations use either a right-angled x / y arrangement, which is produced with appropriately manufactured photolithography or printing masks, or a circular rφ arrangement, which is generated by a rotational movement of the chip surface (rφ-arrays) and a rapidly clocked metering device becomes. This enables densities of up to 1 million test connections per cm 2 or a few square micrometers per individual surface to be achieved.
DNA-Arrays haben die Effektivität dieser Methode in vielen Gebieten der biomedizinischen Forschung bewiesen (für Übersichtsartikel s. Khan et al . in Biochim. Biophys . Acta 1999, 1423: 1117-1128; DeRisi et al . in Nat . Genet . 1996, 14: 457- 460; Debouck and Goodfellow in Nat. Genet. 1999, 21, 48-50;. Der Bedarf an Technologien, die eine hoch parallelisierte De- tektion und Quantifizierung spezifischer Proteine auf der Basis eines schnellen und billigen Tests in einem kleinvolumi- gen Format ermöglichen, ist daher ohne weiteres verständlich. Voraussetzung hierfür ist die Etablierung hochspezifischer, stabiler und regenerierbarer Protein-Arrays bzw. Protein- chips, wofür konventionelle, monoklonale Antikörper prädestiniert sind. Die Hybridomtechnologie ist seit langen etabliert und standardisiert und liefert Antikörper mit der gewünschten Spezifität, Affinität und Stabilität.DNA arrays have proven the effectiveness of this method in many areas of biomedical research (for review articles, see Khan et al. In Biochim. Biophys. Acta 1999, 1423: 1117-1128; DeRisi et al. In Nat. Genet. 1996, 14 : 457-460; Debouck and Goodfellow in Nat. Genet. 1999, 21, 48-50 ;. The need for technologies that enable highly parallelized detection and quantification of specific proteins based on rapid and inexpensive testing in a small volume Enabling the appropriate format is therefore easy to understand, provided that highly specific, stable and regenerable protein arrays or protein chips for which conventional monoclonal antibodies are predestined. Hybridoma technology has long been established and standardized and delivers antibodies with the desired specificity, affinity and stability.
Die Erfindung betrifft somit ein Verfahren zur Herstellung stabiler, regenerierbarer Antikorper-Arrays, bei demThe invention thus relates to a method for producing stable, regenerable antibody arrays, in which
(a) auf der Oberfläche eines planaren Trägers Antikörper- bindungsproteine kovalent immobilisiert werden, die spezifisch den Fc-Teil von Antikörpern erkennen können,(a) covalently immobilizing antibody-binding proteins on the surface of a planar support that can specifically recognize the Fc part of antibodies,
(b) eine Vielzahl von spezifischen monoklonalen Antikörpern unter Musterbildung mit ihrem Fc-Teil an die Antikörperbindungsproteine gebunden werden und (c) die immobilisierten Antikörperbindungsprotein-Antikörper-Komplexe kovalent vernetzt werden.(b) a large number of specific monoclonal antibodies are patterned with their Fc part to the antibody binding proteins and (c) the immobilized antibody binding protein-antibody complexes are covalently crosslinked.
Die Erfindung betrifft ferner einen Antikörper-Array, der nach dem erfindungsgemäßen Verfahren erhältlich ist, ein me- dizinisches oder diagnostisches Gerät, das einen erfindungsgemäßen Antikörper-Array aufweist, sowie einen Kit, der einen erfindungsgemäßen Antikörper-Array sowie Nachweisreagenzien zur qualitativen oder quantitativen Bestimmung von gebundenen Antigenen enthält, die an einen erfindungsgemäßen Antikörper- Array gebunden worden sind.The invention further relates to an antibody array which can be obtained by the method according to the invention, a medical or diagnostic device which has an antibody array according to the invention, and a kit which has an antibody array according to the invention and detection reagents for qualitative or quantitative determination contains bound antigens which have been bound to an antibody array according to the invention.
Die Erfindung gibt ferner die Verwendung eines erfindungsgemäßen Antikörper-Arrays oder eines erfindungsgemäßen medizinischen oder diagnostischen Gerätes zur qualitativen oder quantitativen Bestimmung von Antigenen an. Vorteilhafte und/oder bevorzugte Ausführungsformen der Erfindung sind Gegenstand der Unteransprüche.The invention further specifies the use of an antibody array according to the invention or a medical or diagnostic device according to the invention for the qualitative or quantitative determination of antigens. Advantageous and / or preferred embodiments of the invention are the subject of the dependent claims.
Nach einer Ausführungsform der Erfindung weist der planare Träger eine Oberfläche aus Glas, Metall, Metalloxiden, Halbmetalloxiden oder Kunststoff auf.According to one embodiment of the invention, the planar carrier has a surface made of glass, metal, metal oxides, semimetal oxides or plastic.
Nach einer weiteren Ausführungsform der Erfindung ist das Antikörperbindungsprotein unter Fc-spezifischen Sekundäranti- körpern, Protein A und Protein G ausgewählt.According to a further embodiment of the invention, the antibody binding protein is selected from Fc-specific secondary antibodies, protein A and protein G.
Nach einer Ausführungsform der erfindungsgemäß angegebenen Verwendung ist das zu bestimmende Antigen ein Protein.According to one embodiment of the use specified according to the invention, the antigen to be determined is a protein.
Im folgenden wird die Erfindung ohne Beschränkung detaillierter beschrieben.In the following the invention is described in more detail without limitation.
Das neue Herstellungsverfahren zeichnet sich durch folgendeThe new manufacturing process is characterized by the following
Merkmale aus :Characteristics from:
a) Die spezifischen Antikörper werden »gerichtet« immobili- sert, d.h. über ihren Fc-Teil, um durch die Kopplung die Antigenerkennung nicht zu beeinflussen. Zu diesem Zweck wird ein Raster von Proteinen, die spezifisch den Fc- Teil der spezifischen Antikörper erkennen, kovalent an die betreffende Chipoberfläche gebunden (z. B. derivati- sierte Fc-spezifische Sekundärantikörper oder Protein A- bzw. Protein G-Moleküle) .a) The specific antibodies are "directed" immobilized, i.e. via their Fc part in order not to influence the antigen recognition through the coupling. For this purpose, a grid of proteins that specifically recognize the Fc part of the specific antibodies is covalently bound to the chip surface in question (eg derivatized Fc-specific secondary antibodies or protein A or protein G molecules).
b) Die erforderliche Stabilisierung der immobilisiertenb) The required stabilization of the immobilized
Protein/Antikörper- bzw. Antikörper/Antikörperkomplexe wird durch chemische kovalente Vernetzung erreicht, wo- für entsprechend den Anforderungen gängige Reagenzien eingesetzt werden. Neben der Stabilisierung der Protein- Proteininteraktionen erfolgt auch eine intramolekulare Stabilisierung der spezifischen Antikörper, d. h. eine chemische Vernetzung ihrer Untereinheiten. Es ergeben sich Antikörper-Arrays mit höchster Stabilität, die zum einen eine Dissoziation der speziellen Antikörper, z.B. während der Lagerung, verhindern, zum anderen es aber auch ermöglichen, die Antikörper-Arrays unter stringen- ten Bedingungen zu behandeln, wie hohen Salzkonzentrationen oder niedrigem bzw. hohem pH-Wert, um unspezifische oder niederaffine Interaktionen mit der Antikörpermatrix zu verhindern. Hierdurch wird auch eine entsprechend stringente Vorbehandlung der zu analysierenden Proteingemische ermöglicht.Protein / antibody or antibody / antibody complexes are achieved by chemical covalent crosslinking, where be used for common reagents according to the requirements. In addition to the stabilization of the protein-protein interactions, there is also an intramolecular stabilization of the specific antibodies, ie a chemical cross-linking of their subunits. Antibody arrays with the highest stability result, which on the one hand prevent dissociation of the special antibodies, eg during storage, and on the other hand also make it possible to treat the antibody arrays under stringent conditions, such as high salt concentrations or low or high pH to prevent non-specific or low affinity interactions with the antibody matrix. This also enables a correspondingly stringent pretreatment of the protein mixtures to be analyzed.
c) Der Einsatz kovalent vernetzter Antikörper setzt voraus, dass die Antigenbindungsstelle des betroffenen Antikörpers durch das Vernetzungsreagenz nicht inaktiviert bzw. verändert wird. Als Folge werden daher monoklonale Antikörper gebildet bzw. selektioniert, deren antigen- bindende Eingenschaften durch das einzusetzende Vernetzungsreagens nicht beeinflusst werden. Zur Vernetzung wird beispielhaft verwiesen auf Wehland & Weber in J. Cell Biol., 104 (1987) 1059.c) The use of covalently crosslinked antibodies requires that the antigen binding site of the antibody in question is not inactivated or changed by the crosslinking reagent. As a result, monoclonal antibodies are therefore formed or selected, the antigen-binding properties of which are not influenced by the crosslinking reagent to be used. For networking, reference is made, for example, to Wehland & Weber in J. Cell Biol., 104 (1987) 1059.
Der Gesamtprozess liefert stabile und regenerierbare Antikörper-Arrays . The whole process delivers stable and regenerable antibody arrays.
Claims
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10119308 | 2001-04-19 | ||
| DE10119308 | 2001-04-19 | ||
| DE10162365 | 2001-12-18 | ||
| DE10162365 | 2001-12-18 | ||
| PCT/EP2002/004311 WO2002085926A2 (en) | 2001-04-19 | 2002-04-18 | Method for producing stable, regeneratable antibody arrays |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1379545A2 true EP1379545A2 (en) | 2004-01-14 |
Family
ID=26009128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02745239A Withdrawn EP1379545A2 (en) | 2001-04-19 | 2002-04-18 | Method for producing stable, regeneratable antibody arrays |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20040171068A1 (en) |
| EP (1) | EP1379545A2 (en) |
| JP (1) | JP2004536290A (en) |
| WO (1) | WO2002085926A2 (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7736909B2 (en) * | 2003-01-09 | 2010-06-15 | Board Of Regents, The University Of Texas System | Methods and compositions comprising capture agents |
| EP1599597B1 (en) * | 2003-02-24 | 2010-08-04 | Pritest, Inc. | Translucent solid matrix assay device for microarray analysis |
| ATE428421T1 (en) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | MEDICAL COMPOSITION WITH IMPROVED STABILITY AND REDUCED GELING PROPERTIES |
| US9006240B2 (en) * | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| US20090053236A1 (en) | 2005-11-07 | 2009-02-26 | Eisai R & D Management Co., Ltd. | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| EP2036557B1 (en) * | 2006-05-18 | 2015-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| BRPI0712232A2 (en) * | 2006-06-02 | 2012-01-10 | Koninkl Philips Electronics Nv | detection device, and method for detecting at least one analyte in at least one sample |
| US8865737B2 (en) * | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| CN101600694A (en) * | 2007-01-29 | 2009-12-09 | 卫材R&D管理有限公司 | Composition for treatment of undifferentiated-type of gastric cancer |
| KR20100037590A (en) | 2007-06-08 | 2010-04-09 | 바이오겐 아이덱 엠에이 인코포레이티드 | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
| CA2704000C (en) * | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| JP5991916B2 (en) * | 2009-05-29 | 2016-09-14 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | Peptoid ligand for isolation and processing of autoimmune T cells |
| CA2764153C (en) * | 2009-06-02 | 2021-07-27 | The Board Of Regents Of The University Of Texas System | Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases |
| US8759259B2 (en) * | 2009-10-16 | 2014-06-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for producing cyclic peptoid libraries |
| WO2011162343A1 (en) | 2010-06-25 | 2011-12-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Antitumor agent using compounds having kinase inhibitory effect in combination |
| US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| JP6038128B2 (en) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | A biomarker for predicting and evaluating the reactivity of thyroid and renal cancer subjects to lenvatinib compounds |
| KR20150098605A (en) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Amorphous form of quinoline derivative, and method for producing same |
| NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| RS63559B1 (en) | 2014-08-28 | 2022-10-31 | Eisai R&D Man Co Ltd | High-purity quinoline derivative and method for manufacturing same |
| EP3250588A1 (en) | 2015-01-29 | 2017-12-06 | Board of Trustees of Michigan State University | Cryptic polypeptides and uses thereof |
| PL3263106T3 (en) | 2015-02-25 | 2024-04-02 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| RU2729936C2 (en) | 2015-06-16 | 2020-08-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Anticancer agent |
| RU2718048C2 (en) | 2015-08-20 | 2020-03-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Antitumour therapeutic agent |
| KR20200013644A (en) | 2017-05-16 | 2020-02-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Treatment of Hepatocellular Carcinoma |
| SG11202006677XA (en) | 2018-01-25 | 2020-08-28 | Biogen Ma Inc | Methods of treating spinal muscular atrophy |
| JP7378420B2 (en) | 2018-04-13 | 2023-11-13 | インサイト・コーポレイション | Biomarkers of graft-versus-host disease |
| EP3861347B1 (en) | 2018-10-05 | 2022-12-21 | Eisai R&D Management Co., Ltd. | Biomarkers for a combination therapy comprising lenvatinib and everolimus |
| WO2020071451A1 (en) | 2018-10-05 | 2020-04-09 | Eisai R&D Management Co., Ltd. | Biomarkers for a therapy comprising a sorafenib compound |
| WO2020167715A1 (en) | 2019-02-12 | 2020-08-20 | Biogen Ma Inc. | Biomarkers of progressive multifocal leukoencephalopathy |
| TW202102222A (en) | 2019-03-19 | 2021-01-16 | 美商英塞特公司 | Biomarkers for vitiligo |
| WO2021072098A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| WO2021072116A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| WO2022047419A1 (en) | 2020-08-31 | 2022-03-03 | City Of Hope | Novel cell lines, methods of producing natural killer cells and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5243040A (en) * | 1987-11-20 | 1993-09-07 | Creative Biomolecules | DNA encoding a protein which enables selective removal of immune complexes |
| US5620845A (en) * | 1988-06-06 | 1997-04-15 | Ampcor, Inc. | Immunoassay diagnostic kit |
| AU1360297A (en) * | 1996-01-11 | 1997-08-01 | Australian Membrane And Biotechnology Research Institute | Ion channel sensor typing |
| US6406921B1 (en) * | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| US6713309B1 (en) * | 1999-07-30 | 2004-03-30 | Large Scale Proteomics Corporation | Microarrays and their manufacture |
-
2002
- 2002-04-18 EP EP02745239A patent/EP1379545A2/en not_active Withdrawn
- 2002-04-18 WO PCT/EP2002/004311 patent/WO2002085926A2/en not_active Application Discontinuation
- 2002-04-18 US US10/475,147 patent/US20040171068A1/en not_active Abandoned
- 2002-04-18 JP JP2002583452A patent/JP2004536290A/en not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| See references of WO02085926A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002085926A2 (en) | 2002-10-31 |
| JP2004536290A (en) | 2004-12-02 |
| US20040171068A1 (en) | 2004-09-02 |
| WO2002085926A3 (en) | 2003-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002085926A2 (en) | Method for producing stable, regeneratable antibody arrays | |
| DE19740263C2 (en) | Tiling process for building a chemical array | |
| DE102009012169B3 (en) | Apparatus and method for making a replica or derivative from an array of molecules and applications thereof | |
| DE60126319T2 (en) | IMMOBILIZATION OF BIOPOLYMERS ON AMINated SUBSTRATES THROUGH DIRECT ADSORPTION | |
| EP1277055B1 (en) | Biochip for the archiving and medical laboratory analysis of biological sample material | |
| WO2006072306A1 (en) | Three-dimensional nanostructured and microstructured supports | |
| DE102004021351A1 (en) | Functionalized porous carrier for microarrays | |
| WO2009049838A2 (en) | Surface modification | |
| DE60225593T2 (en) | IMMOBILIZATION OF BINDING MATERIALS | |
| DE60213890T2 (en) | REACTION THROTTLE CHIP AND DETECTION SYSTEM | |
| DE102011010307A1 (en) | Apparatus and method for producing protein microarrays | |
| DE112005003134T5 (en) | Electrically active combinatorial-chemical (electrically-active combinatorial-chemical; eacc) chip for biochemical analyte determination | |
| DE60130211T2 (en) | MATRIX SCREENING PROCESS | |
| WO2003046526A1 (en) | Surface plasmon resonance (spr) sensor surface support | |
| WO2007059839A1 (en) | Method, device and kit for studying macromolecules in a sample | |
| DE102004043870B4 (en) | Method for expanding the dynamic detection range in microarrays | |
| DE10126798A1 (en) | Highly parallel determination of analytes, useful e.g. for diagnostic detection of proteins, by immobilization then contacting with surface carrying specific probes | |
| WO2007085403A2 (en) | Crosslinkable multifunctional carriers for (low-molecular) ligands, use thereof in analytics, and method for the production and crosslinking thereof | |
| WO2003046198A2 (en) | Method for the selection and identification of peptide or protein molecules by means of phase display | |
| WO2003102591A2 (en) | Method for identifying interaction partners using phage display | |
| WO2004089532A1 (en) | Three-dimensional chip | |
| DE10340429A1 (en) | Hydrophobic object with a pattern of hydrophilic areas, its production and use | |
| WO2006015810A2 (en) | Fluorescence-based assays for the rapid quantitative analysis of biomolecules (proteins and nucleic acids) by accumulation on cells or beads | |
| DE202006009728U1 (en) | Microarray assembly includes microporous membrane having different analyte-specific capture molecules (proteins, antibodies or nucleic acids), and incubation chamber arrangement | |
| EP2217364A2 (en) | Flexible extraction method for the production of sequence-specific molecule libraries |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20031014 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20050401 |